Invenio Wealth Partners LLC Buys 98 Shares of Eli Lilly and Company (NYSE:LLY)

Invenio Wealth Partners LLC grew its position in shares of Eli Lilly and Company (NYSE:LLY) by 6.5% during the fourth quarter, HoldingsChannel reports. The institutional investor owned 1,609 shares of the company’s stock after purchasing an additional 98 shares during the period. Invenio Wealth Partners LLC’s holdings in Eli Lilly and Company were worth $1,242,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also modified their holdings of the company. PFC Capital Group Inc. raised its holdings in shares of Eli Lilly and Company by 0.6% during the fourth quarter. PFC Capital Group Inc. now owns 6,290 shares of the company’s stock valued at $4,855,000 after purchasing an additional 40 shares during the last quarter. Geode Capital Management LLC grew its holdings in Eli Lilly and Company by 1.7% during the fourth quarter. Geode Capital Management LLC now owns 17,382,846 shares of the company’s stock valued at $13,389,651,000 after purchasing an additional 291,875 shares during the period. National Wealth Management Group LLC grew its stake in shares of Eli Lilly and Company by 19.0% during the 4th quarter. National Wealth Management Group LLC now owns 326 shares of the company’s stock valued at $252,000 after acquiring an additional 52 shares during the period. Nemes Rush Group LLC boosted its position in shares of Eli Lilly and Company by 6.3% in the fourth quarter. Nemes Rush Group LLC now owns 14,141 shares of the company’s stock worth $10,917,000 after purchasing an additional 835 shares during the period. Finally, Gibson Capital LLC purchased a new stake in Eli Lilly and Company in the 4th quarter worth $264,000. Institutional investors own 82.53% of the company’s stock.

Insider Activity

In related news, CAO Donald A. Zakrowski sold 1,000 shares of the firm’s stock in a transaction on Thursday, March 13th. The stock was sold at an average price of $818.24, for a total value of $818,240.00. Following the completion of the transaction, the chief accounting officer now owns 5,840 shares in the company, valued at $4,778,521.60. This trade represents a 14.62 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Corporate insiders own 0.13% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages have issued reports on LLY. Truist Financial increased their price objective on shares of Eli Lilly and Company from $1,029.00 to $1,038.00 and gave the company a “buy” rating in a report on Monday, February 3rd. Wells Fargo & Company boosted their price objective on Eli Lilly and Company from $970.00 to $1,100.00 and gave the stock an “overweight” rating in a research note on Wednesday, March 5th. Citigroup cut their price objective on shares of Eli Lilly and Company from $1,250.00 to $1,190.00 and set a “buy” rating on the stock in a research report on Tuesday, January 28th. Berenberg Bank set a $970.00 price target on Eli Lilly and Company in a report on Thursday, January 16th. Finally, StockNews.com raised shares of Eli Lilly and Company from a “hold” rating to a “buy” rating in a research note on Friday, February 7th. Three investment analysts have rated the stock with a hold rating and eighteen have given a buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $1,009.72.

Eli Lilly and Company Stock Up 0.4 %

Shares of Eli Lilly and Company stock opened at $825.42 on Tuesday. Eli Lilly and Company has a 52-week low of $711.40 and a 52-week high of $972.53. The firm’s 50 day moving average price is $846.30 and its 200-day moving average price is $835.00. The company has a quick ratio of 0.97, a current ratio of 1.15 and a debt-to-equity ratio of 2.00. The company has a market cap of $782.64 billion, a P/E ratio of 70.49, a PEG ratio of 1.40 and a beta of 0.34.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings results on Thursday, February 6th. The company reported $5.32 EPS for the quarter, missing analysts’ consensus estimates of $5.45 by ($0.13). Eli Lilly and Company had a net margin of 23.51% and a return on equity of 85.24%. On average, sell-side analysts predict that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Eli Lilly and Company declared that its Board of Directors has initiated a stock repurchase program on Monday, December 9th that permits the company to repurchase $15.00 billion in shares. This repurchase authorization permits the company to repurchase up to 2% of its stock through open market purchases. Stock repurchase programs are typically an indication that the company’s leadership believes its stock is undervalued.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.